There are two distinct cholinesterases: acetylcholinesterase, responsible for acetylcholine hydrolysis at the neuromuscular junction, and the less specific enzyme, cholinesterase (acylcholineacylhydrolase). The latter enzyme is found in most human tissues including the plasma, but not the red cells, and its function is unknown.
the karyotype 45,XY or XX, G-, G-(GqGq)+. The latter two types are those associated with familial mongolism, while the most frequent type is the first, which may be the commonest exchange aberration detectable in mitotic cells (Court Brown 1967) .
Structural heterozygosity in man has to be considered from the standpoint of reproductive fitness. The events at meiosis in structural heterozygotes can result in the production of gametes with duplication deficiencies, and on theoretical grounds it would be expected that the fertility of structural heterozygotes would be impaired. If this is so then there is remarkably little evidence for it, so far, from the examination of heterozygotes and their families identified in population studies, with the major exception of the centric fusion types of translocation. However, even among the latter is seems that not every individual with a karyotype of 45,XY or XX, D-, D-(DqDq) + has impaired fertility as evinced by a detectably increased pre-natal mortality rate. There is a general tendency at present to regard cytogenetic studies as being of unusual value in determining the reasons for repeated abortion in man. There is, however, little evidence to support this and much of the claimed value may be due to faulty epidemiology and to ascribing too much significance to minor variations in the human karyotype which are quite common, such as the unusual length of a short arm of an acrocentric autosome. Vogel 1959 , Kalow 1962 ) is concerned with the genetical components of variability in individual responses to drugs. With the development of more numerous and increasingly powerful and specific drugs, unexpected and usually unwanted reactions are multiplying, some of which will be described in detail by subsequent speakers.
My task in this symposium is to consider the scope and limitations of pharmacogenetics and I shall do this by discussing in a general way genetic polymorphism and the biochemistry of a few typical situations.
Mutants arising from mutations which are very rare events (say 1 in 100,000) are usually less fit than the forms from which they originate and are consequently rapidly eliminated from a population. Changes which occur at appreciable frequencies (1 in 20 or more) as do some of the genes responsible for increased drug sensitivity, carry disadvantages which must in any such population be counterbalanced by advantages. Such a balance can be maintained in several ways, of which I shall mention only two: (1) Heterozygote advantage, that is a situation where the fitness of the heterozygote surpasses the fitness of both homozygotes.
(2) A composite environment providing separate niches which differ in their relative suitability for the several genotypes.
While the problems of genetical balance are not specific to pharmacogenetics we may ask how it is that we find so many instances of established polymorphism concerning substances like primaquine or isoniazid, which are recent laboratory products and to which human populations have not been previously exposed? I think the answer must be that these genetical equilibria have not been established by the actions of the drugs which reveal their existence, but by other different selective agencies.
The quest for selective agencies, which might be responsible for such pharmacological diversity is hampered by many difficulties, most of all by the impossibility of direct demonstration and by the rapid and accelerating changes of human environment during historical times. In many cases one must guess at the effects of past conditions of nutrition, diseases and mating systems which do not at present prevail. Nevertheless a few tentative inferences can be drawn and these can sometimes be supported by additional evidence. It has for instance been found (Harris & Whittaker 1961 ) that the atypical pseudocholinesterase discovered through the application of muscle relaxants withstands inhibition by a substance in potato extracts, possibly solanin, better than the normal enzyme. Thus the genes responsible for different degrees and modes of esterase acetylation might be maintained in equilibrium by noxious substances, which commonly occur in natural food.
The G-6-PD deficiency gene not only produces an increased sensitivity to primaquine and other antimalarials and drugs which are of recent synthesis and application but probably also confers some protection against malaria (Adinolfi et al. 1963 ) which is of long standing in the old world. This complex situation is in addition complicated by the fact that the G-6-PD deficiency is also the cause of favism, occasionally a fatal hemolytic disease in certain Mediterranean areas caused by the eating of raw broad beans and known since classical antiquity, and which possibly was the cause for the prohibition of bean eating by the Pythagoreans.
The way in which the introduction of a new class of drugsthe barbituratescan reveal a widespread but largely hidden genetical polymorphism has been shown in family studies of white South Africans by Dean & Barnes (1955) ; here a dominant gene predisposed to greatly varying forms of porphyria.
'Tasters' and 'nontasters' for phenylthiocarbamide (Harris & Kalmus 1949) may show different metabolic responses to goitrogenic substances of the N-C= S class, some of which occur in vegetables of the cabbage family and may also be ingested with the milk from cows fed on kale. In any case 'tasters' and 'nontasters' show differences in the incidence of several thyroid diseases (Kalmus 1963) .
The dextran sensitivity of rats promises to widen the pharmacogenetical field for behavioural and possibly even social studies. It has been shown (Harris et al. 1963 ) that the anaphylactoid reaction produced in most Norwegian rats by injection of dextran or egg white is suppressed in a minority by a recessive autosomal gene dx, which occurs at high frequency in many laboratory stocks and also in wild populations. Several pharmacological and metabolic consequences of these differences have been described, but possibly most interesting is a greatly increased resistance of the dextran-insensitive rats to traumatic shock, tourniquet injury (Gecse et al. 1964 ) and to heat shock. Considering that rats have been observed (Barnett 1963) to die from social stress (aggression), a hereditary generalized increase in resistance to stresses might be of considerable survival value.
It would appear that all the better-analysed instances of pharmacogenetical diversity are in fact enzyme polymorphisms and thus are only special instances of a much more general situation (Harris 1966) . That they are being discovered in increasing numbers due to the testing of new drugs both in laboratory animals and in patients demonstrates the biochemical specificity of modern drugs.
